The FDA has approved pembrolizumab immunotherapy, the first treatment to lower kidney cancer recurrence risk after surgery. UT Southwestern's Dr. Hans Hammers helps patients explore its benefits and risks.
A new immunotherapy drug combination has been dubbed a significant advancement in kidney cancer treatment. The combination of ipilimumab and nivolumab can improve outcomes and quality of life. Learn more.
Hans Hammers, M.D., Ph.D. /
James Brugarolas, M.D., Ph.D.
